Effects of Prokinetics on the Digestive Tract.
Prokinetics
constipation
functional gastrointestinal disorders
gastric emptying
safety
small bowel motility
Journal
Current reviews in clinical and experimental pharmacology
ISSN: 2772-4336
Titre abrégé: Curr Rev Clin Exp Pharmacol
Pays: Netherlands
ID NLM: 9918227368306676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
12
2020
revised:
04
05
2021
accepted:
24
05
2021
pubmed:
31
8
2021
medline:
5
4
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
Functional gastrointestinal disorders account for at least a third of visits to gastroenterology clinics. Despite pathophysiological complexity, impaired gut motility may be frequently present in these disorders. Prokinetics are a class of drugs that promote gastrointestinal motility, accelerate transit, and potentially improve digestive symptoms. Several prokinetic agents with a great variety of mechanisms of action are available. The purpose of this paper is to update our current knowledge about the efficacy and safety of prokinetics. A literature search on efficacy and safety of prokinetics was carried out using the online databases of Pubmed, Medline, and Cochrane. Based on the action of different receptors, prokinetics mainly comprise dopamine antagonists, 5HT4 agonists, motilin agonists, ghrelin agonists, and cholinergic agonists. Prokinetics have the potential to improve motility function in all segments of the digestive tract, from the esophagus to the colon. In particular, drug international agencies have approved antidopaminergic metoclopramide for the treatment of gastroparesis and serotoninergic prucalopride for chronic constipation not responsive to traditional laxatives. Arrhythmias by QT prolongation and galactorrhea by prolactin stimulation are the more frequent side effects related to prokinetics use. Old and new prokinetics are effective in ameliorating digestive motility disorders and related symptoms and are widely prescribed. Special attention should be paid to the potential adverse events of these agents.
Sections du résumé
BACKGROUND
Functional gastrointestinal disorders account for at least a third of visits to gastroenterology clinics. Despite pathophysiological complexity, impaired gut motility may be frequently present in these disorders.
INTRODUCTION
Prokinetics are a class of drugs that promote gastrointestinal motility, accelerate transit, and potentially improve digestive symptoms. Several prokinetic agents with a great variety of mechanisms of action are available.
AIM
The purpose of this paper is to update our current knowledge about the efficacy and safety of prokinetics.
METHODS
A literature search on efficacy and safety of prokinetics was carried out using the online databases of Pubmed, Medline, and Cochrane.
RESULTS
Based on the action of different receptors, prokinetics mainly comprise dopamine antagonists, 5HT4 agonists, motilin agonists, ghrelin agonists, and cholinergic agonists. Prokinetics have the potential to improve motility function in all segments of the digestive tract, from the esophagus to the colon. In particular, drug international agencies have approved antidopaminergic metoclopramide for the treatment of gastroparesis and serotoninergic prucalopride for chronic constipation not responsive to traditional laxatives. Arrhythmias by QT prolongation and galactorrhea by prolactin stimulation are the more frequent side effects related to prokinetics use.
CONCLUSION
Old and new prokinetics are effective in ameliorating digestive motility disorders and related symptoms and are widely prescribed. Special attention should be paid to the potential adverse events of these agents.
Identifiants
pubmed: 34455950
pii: CRCEP-EPUB-117091
doi: 10.2174/2772432816666210805125813
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-165Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.